News and publications

NeoPrecis Beats Tumor Mutation Burden as a Predictor of Immunotherapy Response

By combining MHC-I/II neoantigen immunogenicity with tumor clonal architecture, NeoPrecis outperforms TMB across five melanoma and three NSCLC cohorts.

More news

Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Open Data
News
October 2026
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
QB3
News
October 2026
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
Learning What Cancer Reveals: Introducing NEMo
bioRxiv Preprint
Publication
September 2026
Learning What Cancer Reveals: Introducing NEMo
Learning What Cancer Reveals: Introducing NEMo
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
QB3
News
June 2026
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
See all
news